Chen et al. (2020)3636 Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395 (10223):507–513
|
Retrospective review |
99 |
Confusion (9%) and headache (8%) |
Chen et al. (2020)3737 Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;368:m1091
|
Retrospective study |
113 |
Headache (11%) and dizziness (8%) |
Giacomelli et al. (2020)3838 Giacomelli A, Pezzati L, Conti F, et al. Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study. Clin Infect Dis 2020; 71(15):889–890
|
Cross-sectional study |
59 |
Olfactory/or taste dysfunction (34%) |
Hopkins et al. (2020)3939 Hopkins C, Surda P, Whitehead E, Kumar BN. Early recovery following new onset anosmia during the COVID-19 pandemic - an observational cohort study. J Otolaryngol Head Neck Surg 2020;49(01):26
|
Observational cohort |
382 |
Anosmia (86%) |
Huang et al. (2020)4040 Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395 (10223):497–506
|
Prospective study |
41 |
Headache (8%) |
Klok et al. (2020)4141 Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020;191:145–147
|
Retrospective review |
184 |
CVA (1.6%) |
Li et al. (2020)4242 Li Y, Li M, Wang M, et al. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. Stroke Vasc Neurol 2020;5(03):279–284
|
Retrospective review |
221 |
CVA (6%) and CVT (0.5%) |
Lodigiani et al. (2020)4343 Lodigiani C, Iapichino G, Carenzo L, et al; Humanitas COVID-19 Task Force. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res 2020;191:9–14
|
Retrospective review |
338 |
CVA (2.5%) |
Mao et al. (2020)1515 Mao L, Jin H, Wang M, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol 2020;77(06):683–690
|
Retrospective review |
214 |
Headache (13%), dizziness (17%), impaired consciousness (8%), CVA (3%), dysosmia (5%), and dysgeusia (6%) |
Wan et al. (2020)4444 Wan S, Xiang Y, Fang W, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol 2020;92 (07):797–806
|
Retrospective review |
135 |
Headache (35%) |
Wang et al. (2020)4545 Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020;323(11):1061–1069
|
Retrospective review |
138 |
Headache (7%) and dizziness (9%) |
Wang et al. (2020)4646 Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis 2020;71(15):769–777
|
Retrospective review |
69 |
Headache (14%) and dizziness (7%) |
Yang et al. (2020)4747 Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020;8(05):475–481
|
Retrospective review |
52 |
Headache (6%) |
D et al. (2021)3333 D V,Sharma A, Kumar A, Flora SJS. Neurological Manifestations in COVID-19 Patients: A Meta-Analysis. ACS Chem Neurosci 2021;12 (15):2776–2797
|
Meta-analysis |
6,804 |
Guillain-Barré syndrome (0.8%) |
D et al. (2021)3333 D V,Sharma A, Kumar A, Flora SJS. Neurological Manifestations in COVID-19 Patients: A Meta-Analysis. ACS Chem Neurosci 2021;12 (15):2776–2797
|
Meta-analysis |
53,981 |
Encephalitis (0.1%) |
D et al. (2021)3333 D V,Sharma A, Kumar A, Flora SJS. Neurological Manifestations in COVID-19 Patients: A Meta-Analysis. ACS Chem Neurosci 2021;12 (15):2776–2797
|
Meta-analysis |
6,607 |
Encephalopathy (10.4%) |
Finsterer et al. (2021)3434 Finsterer J, Scorza FA, Scorza CA, Fiorini AC. Peripheral neuropathy in COVID-19 is due to immune-mechanisms, pre-existing risk factors, anti-viral drugs, or bedding in the Intensive Care Unit. Arq Neuropsiquiatr 2021;79(10):924–928 [online]
|
Literature review |
261 |
Nerve compression syndrome (7%) |
Rifino et al. (2021)4848 Rifino N, Censori B, Agazzi E, et al. Neurologic manifestations in 1760 COVID-19 patients admitted to Papa Giovanni XXIII Hospital, Bergamo, Italy. J Neurol 2021;268(07):2331–2338 [Internet]
|
Retrospective study |
1,760 |
CVD (38%), CVT (0.7%), GBS (12.4%), CIP (6.6%), and encephalitis (3.6%) |
Zhao et al. (2020)2222 Zhao K, Huang J, Dai D, Feng Y, Liu L, Nie S. Acute myelitis after SARS-CoV-2 infection: a case report. medRxiv [Internet]. 2020;3 (16):20035105
|
Case report |
1 |
Acute myelitis |
Zhang et al. (2021)2121 Zhang T, Hirsh E, Zandieh S, Rodricks MB. COVID-19-Associated Acute Multi-infarct Encephalopathy in an Asymptomatic CADA-SIL Patient. Neurocrit Care 2021;34(03):1099–1102
|
Case report |
1 |
ADEM |